Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced solid tumor
Dose-escalation phase: Histologically confirmed, newly diagnosed or relapsed/ refractory unresectable American Joint Committee on Cancer (AJCC) Stage IIIC or IV disease
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Adequate liver, renal and bone marrow function
You may not be if
Participants for whom standard therapy exists and is considered appropriate by the investigator
Prior treatment with an inhibitor of BRAF (sorafenib allowed)
Active Central nervous system (CNS) lesions, or history of or known carcinomatous meningitis
Treatment with any chemotherapy, radiotherapy, immunotherapy or investigational agent within 28 days prior to first dose of study drug
Anticipated or ongoing anti-cancer therapies other than those administered in this study
Serious cardiovascular illness within the 6 months prior to study drug administration
Clareo Health | A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors
